flipping the script
Research Funded
$5,000,000+
We have funded over $5M in brain cancer research grant proposals
45+
We have funded over 45 clinical trials / research grants
25+
We have partnered with over 25 leading institutions across the country to fund innovative research
Featured Research
2019
GBM Agile
$500,000 granted
GBM Agile (Glioblastoma Adaptive Global Innovative Learning Environment) is the world’s first “adaptive clinical trial platform.” It is led by key opinion leaders in the GBM field and has the collective support of an international group of more than 130 clinicians, researchers, biostatisticians, imagers, pathologists, and leaders from government and industry. We helped launch this trial and there are now 40+ trial sites across 3 regions represented.
40+ active trial sites
In partnership with National Brain Tumor Society (NBTS) and other funders
2021 - 2024
Glioma Connectome Project (GCP)
$643,786 granted
A consortium of 8 top tier academic research centers, including Henry Ford, Lenox Hill, Northwestern, UMiami, UNebraska, UPenn, UPMC, and UTexas – Houston. This project leverages machine learning to utilize information about how the brain is organized (connectomics) and how it relates to the patient’s experience, in an effort to better care for brain tumor patients.
Henry Ford, Lenox Hill, Northwestern, UMiami, UNebraska, UPenn, UPMC, and UTexas - Houston
2024
UMiami
$250,000 GRANTED
Dolphins Cancer Challenge (DCC) and StacheStrong have teamed up to raise funds and awareness for brain cancer research. The philanthropic partnership, which commits to contributing $1 million over four years to Sylvester Comprehensive Cancer Center, a part of the University of Miami Miller School of Medicine, was formally announced July 17, Glioblastoma Awareness Day.
Dr. Shah
In partnership with Dolphins Cancer Challenge
Grants & Research Funded
2024
UMiami
$250,000 GRANTED
The Shah Laboratory (The Section of Virology and Immunotherapy) researches the interplay between viruses and brain tumors. Dr. Shah is focused on developing translational therapies to target cancer-promoting viruses in glioblastoma and enhance anti-tumor immune responses. Using novel gene and cellular therapies, the Shah lab aims to eliminate brain cancer-stem cells which are responsible for treatment resistance and tumor recurrence.
Dr. Shah
In partnership with Dolphins Cancer Challenge
2024
Northwestern
$200,000 GRANTED
Translational grant seeking a better understanding of cellular responses to extensive clinical treatments with the ultimate goal of developing new cures for children with high grade gliomas.
Dr. Li
In partnership with the Dick Vitale Pediatric Cancer Research Fund and the V Foundation
2024
Children's Hospital of Los Angeles and University of Utah
$25,000 GRANTED
Experimental validation of AI/ML-identified therapeutic targets in glioblastoma.
Dr. Tsai and Dr. Alter
In partnership with The Musella Foundation
2024
Brigham and Women's
$200,000 GRANTED
Year 2 of the development of therapeutic miR-10b gene editing. MiR-10b is highly abundant in adult gliomas and appears to be essential for the viability of glioma cells. This study is anticipated to present a common therapeutic strategy for GBM and other gliomas.
Dr. Krichevsky
In partnership with National Brain Tumor Society (NBTS)
2024
University of Pittsburgh Medical Center
$50,000 GRANTED
A multicenter study to assess the feasibility of Gleolan (ALA / Aminolevulinic Acid HCI) in pediatric brain tumor patients after delayed administration. In conjunction with UPMC, Children’s Hospital of Pittsburgh, Advocate Midwest Children’s Brain Tumor Center and additional study sites in future.
Dr. Hadjipanayis
In partnership with Musella Foundation
2024
Society of Neurological Surgeons
$55,000 GRANTED
Cohort II of Society of Neurological Surgeons (SNS) Training Program: Formal mentored research program for 2 years for neurosurgery residents. Goal is to improve human health by providing participants with the skills, mentorship, education and experience needed.
2024
UCSD
$60,000 granted
Year 2 of postdoctoral fellowship focused on targeting bromodomain containing two protein to inhibit mesenchymal transition in recurrent glioblastoma.
Dr. Vadla
In partnership with American Association for Cancer Research (AACR)
2023
UCLA
$25,000 granted
Investigation of anti-angiogenic treatment resistance in glioblastoma.
Dr. Yang
In partnership with The Musella Foundation
2023
UIllinois Cancer Center
$25,000 granted
Targeting of glioblastoma stem cells by miRNA.
Dr. Yamada
In partnership with The Musella Foundation
2023
Harvard Medical School
$35,000 granted
Computer modeling of tumor treating fields.
Dr. Haack
In partnership with The Musella Foundation
2021 - 2024
Glioma Connectome Project (GCP)
$643,786 granted
8 leading research centers (Henry Ford, Lenox Hill, Northwestern, UMiami, UNebraska, UPenn, UPMC, UTexas-Houston) use machine learning to improve brain tumor patient care by analyzing brain organization (connectomics) and patient experience data.
2023
Columbia University
$25,000 granted
Test blocking of the CD47/SIRPa pathway during radiation.
Dr. Gartrell
In partnership with The Musella Foundation
2023
UChicago
$50,000 granted
Creation of a peptide vaccine targeting multiple cytomegalovirus antigens in malignant brain tumors.
Dr. Thompson
In partnership with The Musella Foundation
2023
UCLA
$200,000 granted
Testing two clinical drugs to determine if they promote GBM cell death in preclinical GBM models.
Dr. Nathanson and Dr. Cloughhesy
In partnership with National Brain Tumor Society (NBTS)
2023
Duke
$100,000 granted
Glioblastoma biobank project, which Includes a survey portal for GBM patients to collect medical history and demographics, while also including blood and serum collection for genetic analysis.
Dr. Ostrom and Dr. Walsh
In partnership with Glioblastoma Research Organization (GBMRO)
2023
UCSD
$66,000 granted
Postdoctoral fellowship focused on targeting bromodomain containing two protein to inhibit mesenchymal transition in recurrent glioblastoma.
Dr. Vadla
In partnership with American Association for Cancer Research (AACR)
2023
UCSF & Brigham and Women's
$200,000 granted
Clinical study to test the safety and feasibility of implanting a microdevice into GBM patients’ tumors to deliver microdoses of up to 20 different drugs into different areas in the tumor. The tumor and device would then be removed to assess the tumor biomarkers and response to the drugs.
Dr. Hervey-Jumper and Dr. Jones
In partnership with American Brain Tumor Association (ABTA)
2022
Weill Cornell
$40,023 granted
Targeting cancer-associated fibroblasts in irradiated pediatric brain tumors.
Dr. Vanpouille-Box
“Solely funded by StacheStrong”
2022
Brigham and Women’s
$200,000 granted
Development of therapeutic miR-10b gene editing. MiR-10b is highly abundant in adult gliomas and appears to be essential for the viability of glioma cells. This study is anticipated to present a common therapeutic strategy for GBM and other gliomas.
Dr. Krichevsky
In partnership with National Brain Tumor Society (NBTS)
2022
Society of Neurological Surgeons
$110,000 granted
Launched Society of Neurological Surgeons (SNS) Training Program: Formal mentored research program for 2 years for neurosurgery residents. Goal is to improve human health by providing participants with the skills, mentorship, education and experience needed.
2021
Ivy Brain Tumor Center
$340,000 granted
Phase 0/1 clinical trial of sonodynamic therapy for patients with recurrent glioblastoma multiforme and recurrent high-grade gliomas. This novel drug-device combination has the potential to become a new treatment modality for patients with brain cancer.
Dr. Sanai
In partnership with Barrow Neurological Foundation
2021
Duke
$148,620 granted
Assess how individual cells evolve and adapt over time and in response to therapy. Gene expression profiling at this level will aid in the identification of particular therapeutic sensitivities that may be present and otherwise unseen based on traditional sequencing methods.
Dr. Pirozzi
“Solely funded by StacheStrong”
2021
Yale
$1,000,000 granted
Support NBTS’ launch of the targeting DNA damage response in glioma (TDG) consortium. This is a collaboration of world-class researchers advancing an emerging and promising, but underdeveloped, area of cancer research.
Dr. Bindra
In partnership with National Brain Tumor Society (NBTS)
2021
UMiami
$50,000 granted
Discovery grant investigating the role of CD97/ADGRE5 receptor in glioblastoma invasion and its mechanism of action in the brain.
Dr. Eichberg
In partnership with Neurosurgery Research & Education Foundation (NREF)
2021
UCSF
$50,000 granted
Discovery grant focused on in vivo gene screening and transcriptome editing with retroviral-delivered CRISPR-Cas for the treatment of glioblastoma.
Dr. Young
In partnership with Neurosurgery Research & Education Foundation (NREF)
2020
Northwestern
$50,000 granted
Developing a patient-derived b-cell-based vaccine, a novel therapeutic agent for glioblastomas.
Dr. Castro
In partnership with Neurosurgery Research & Education Foundation (NREF)
2020
Mount Sinai NYC
$100,000 granted
Trial evaluated the safety, efficacy, and feasibility of delivering a therapeutic vaccine to patients made up of their own dendritic cells (isolated from blood samples), loaded with individualized multiple neoantigens made from synthetic peptides created in the laboratory and based on the specific alterations found in a patient’s tumor tissue.
Dr. Hormigo
In partnership with National Brain Tumor Society (NBTS)
2019
GBM Agile
$500,000 granted
Assist in the operationalization and launch of GBM AGILE (Glioblastoma Adaptive Global Innovative Learning Environment), the world’s first global “adaptive” clinical trial for brain cancer.
In partnership with National Brain Tumor Society (NBTS) and other funders
